Featured Story | By Nick Paul Taylor Bristol Myers Squibb came to the rescue of a beleaguered BridgeBio today, striking a $905 million biobuck deal to secure a rival to oncology candidates in development at Merck, Novartis, Roche, Sanofi and more. read more |
| |
|---|
|
Top Stories By Gabrielle Masson Usama Malik—former CFO at Immunomedics and, more recently, CEO of Fore Biotherapeutics—has been formally indicted for insider trading, securities fraud and securities fraud conspiracy after allegedly sharing insider information with his then-girlfriend. read more By Annalee Armstrong At Caribou Biosciences’ upcoming 10th birthday party celebration, the chardonnay will be flowing. That’s because the biotech is uncorking first-in-human data for its CAR-T cell therapy that CEO Rachel Haurwitz believes are better than the three approved lymphoma treatments in the class. read more By Gabrielle Masson Bristol Myers Squibb just released new two-year deucravacitinib data showing lasting efficacy and safety for patients with moderate to severe plaque psoriasis. The company anticipates launching the drug in September, when it would go up against Amgen’s Otezla. read more By Max Bayer Taiho is coughing up nearly $250 million in upfront cash to claw back some licensing rights of its licensing med originally handed off to Cullinan Oncology three years ago. The extension of the two companies' collaboration comes as the lung cancer med at the center of the dealmaking nears a pivotal phase 2 trial. read more By Nick Paul Taylor Jan Poth has ended a near-20-year stint at Boehringer Ingelheim to take up a CEO position in biotech. SciRhom has hired the Boehringer veteran to replace its co-founder, giving the Munich-based company a deep well of experience to draw on as it advances a pipeline of autoimmune candidates. read more By Gareth Macdonald Involving a broader cross section of physicians in trials would aid efforts to recruit people from underrepresented groups, say Abbott and Women as One, which have launched a training program with this in mind. read more By Andrea Park The U.S. Federal Trade Commission has ordered Medtronic and Intersect ENT to adjust the terms of their $1.1 billion acquisition deal before finally tying it off. read more By Kevin Dunleavy A police report of the domestic abuse arrest of Seagen CEO Clay Siegall, Ph.D., describes a drunken night involving him, his wife and another couple and includes sexual escapades and violence that led Siegall to be taken to jail. read more By Dave Muoio Median hourly wages for contract nurses rose a whopping 106% from 2019 to 2022 ($64 in 2019 compared to $132 in 2022), while wages for employed nurses increased 11% over the same period ($35 in 2019 compared to $39 in 2022). read more By Fraiser Kansteiner Economic and geopolitical circumstances—namely a renewed COVID-19 outbreak in China and Russia’s continued aggression in Ukraine—have put a squeeze on global supply chains and prompted a spike in operational costs, Merck KGaA said. read more By Zoey Becker Aurobindo Pharma's Hyderabad manufacturing facility was issued a Form 483 from the FDA after the agency found six observations during a recent inspection. read more Resources Sponsored by: Catalent In this executive summary, we describe the benefits of controlled release, look at how to determine whether a drug is suitable for controlled release, review the application of PBPK modelling in controlled release formulation development and discuss how modified release products can be developed to deliver optimal patient outcomes. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: H1 More than 570 clinical trials in Ukraine have been disrupted. Unanticipated disruptions to medical testing and clinical trials impede progress toward new breakthroughs and new therapies that millions of patients around the world hang their hope on. What role do rescue sites play? Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. | 
